Hepion Pharmaceuticals (NASDAQ:HEPA) Trading Up 4.2% – Time to Buy?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) shares traded up 4.2% during mid-day trading on Monday . The stock traded as high as $0.49 and last traded at $0.47. 74,451 shares were traded during mid-day trading, an increase of 17% from the average session volume of 63,626 shares. The stock had previously closed at $0.45.

Hepion Pharmaceuticals Stock Up 4.2 %

The firm has a market capitalization of $3.26 million, a P/E ratio of -0.11 and a beta of 1.70. The business’s 50-day simple moving average is $0.58 and its 200 day simple moving average is $0.68.

Institutional Investors Weigh In On Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP bought a new stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned approximately 3.33% of Hepion Pharmaceuticals as of its most recent SEC filing. 17.24% of the stock is currently owned by institutional investors.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.